-

09:39:05 AM

TLSA Stock News

TLSA - Tiziana Life Sciences Ltd

06/05/23 10:00 AM

Nasdaq : TLSA

Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis

Results confirm positive signal previously reported in the first two Expanded Access patients who both subsequently demonstrated clinical improvements Phase 2a trial in na-SPMS on track to begin in Q3 2023 KOL webinar with Howard L. Weiner, M.D., Chairman of Tiziana's Scientific Advisory Board and

RHEA-AI

neutral

05/25/23 7:00 AM

Nasdaq : TLSA

conferences

Tiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (SPMS)

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today

RHEA-AI

neutral

05/23/23 7:00 AM

Nasdaq : TLSA

Tiziana Life Sciences Announces Participation on the Webull Corporate Communications Service Platform

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that they are now participating on the new Webull

RHEA-AI

positive

05/17/23 7:00 AM

Nasdaq : TLSA

Tiziana Life Sciences Announces Chief Medical Officer Invited to Give Presentation on Intranasal Foralumab on May 17

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that its Chief Medical Officer is presenting at the

RHEA-AI

very positive

04/27/23 7:00 AM

Nasdaq : TLSA

Tiziana Life Sciences Announces Findings from Intranasal Anti-CD3 mAb Treatment in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference

There are no effective treatments for intracerebral hemorrhage (ICH), which has a 30% to 40% mortality rate Intranasal anti-CD3 mAb treatment showed a reduction in Intracerebral Hemorrhage injury severity Intranasal foralumab could represent a novel therapeutic approach for treating ICH and

RHEA-AI

neutral

04/26/23 2:47 PM

Nasdaq : TLSA

Tiziana Life Sciences Ltd Reports Annual Results for the Twelve Months Ended December 31, 2022, and Corporate Update

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced financial results for the twelve months ended

RHEA-AI

positive

04/24/23 7:00 AM

Nasdaq : TLSA

Tiziana Life Sciences Ltd. Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that it has received a notification from the Nasdaq

RHEA-AI

neutral

04/20/23 7:00 AM

Nasdaq : TLSA

Tiziana Life Sciences to File Alzheimer’s IND for Intranasal Foralumab in Q2 2023

Application for $3M of non-dilutive funding for Phase 2a Alzheimer’s trial will be submitted in Q2 2023 Tiziana guided by FDA Type “B” meeting comments on its scheduled Q2 2023 intranasal foralumab Alzheimer’s IND filing Alzheimer’s patients will be administered 3-months of intranasal foralumab to

RHEA-AI

neutral

04/18/23 7:00 AM

Nasdaq : TLSA

Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes

CD3 antibody has emerged as an established and attractive target for Type 1 diabetes after the $2.9 billion acquisition of Provention Bio by Sanofi Mechanism of Action of Tiziana’s first-in-class, only fully human CD3 antibody, intranasal foralumab, makes it an ideal candidate for Type 1 diabetes

RHEA-AI

very positive

04/17/23 9:00 AM

Nasdaq : TLSA

Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences’ (NASDAQ:TLSA) First-in-Class Foralumab Is Showing Promise

Research is being done into whether there might be treatments that tackle Multiple Sclerosis (MS) through immunosuppression and a reduction of patient neuroinflammation. Anti-CD3 monoclonal antibodies are treatments that seek to reduce inflammation in the

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

TLSA Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.tizianalifesciences.com
Security nameTiziana Life Sciences Ltd
Issue typecs
SectorManufacturing
Sic code2834
Employees14
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing

About Tiziana Life Sciences Ltd

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.